29958-08-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(Methylthio)-5-aminopyridine is used as a key intermediate in the synthesis of various drugs, contributing to the development of new therapeutic agents. Its presence in the molecular structure of these drugs allows for the modulation of biological activities and the enhancement of pharmacological properties.
Used in Agrochemical Industry:
2-(Methylthio)-5-aminopyridine is utilized as a building block in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds enables the improvement of their efficacy and selectivity, leading to more effective crop protection and management.
Used in Organic Synthesis:
2-(Methylthio)-5-aminopyridine serves as a valuable reagent in organic synthesis, facilitating the formation of complex organic molecules. Its unique functional groups allow for various chemical reactions, making it a versatile component in the synthesis of a wide range of organic compounds.
Used in Medical Research:
2-(Methylthio)-5-aminopyridine is being investigated for its potential medical uses, particularly in the treatment of neurological disorders. Its unique chemical properties and interactions with biological systems make it a promising candidate for the development of novel therapeutic agents targeting neurological conditions.

InChI:InChI=1/C6H8N2S/c1-9-6-3-2-5(7)4-8-6/h2-4H,7H2,1H3

Upstream product

• 20885-21-6 3-nitro-6-(methylthio)pyridine 
• 13534-97-9 6-bromopyridine-3-amine 
• 5188-07-8 sodium thiomethoxide 
• 4548-45-2 2-chloro-5-nitropyridine 

Downstream Products

• 1293979-17-5 C₁₃H₁₀F₂N₂OS 
• 183988-47-8 N-(6-Methylsulfanyl-pyridin-3-yl)-2-(2-oxo-2-phenyl-ethylsulfanyl)-acetamide 
• 34392-80-8 sulfanilic acid-(6-methylsulfanyl-[3]pyridylamide) 

Relevant academic research and scientific papers

Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists

GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119

N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy

A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC50 of 0.38 μM and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure-activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro- benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure-activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.

Synthesis of 4- and 6-azaindoles via the fischer reaction

Contrary to the common idea that Fischer indole cyclization often cannot be effectively applied to the synthesis of the corresponding azaindoles, we show that this approach can be actually very efficient for the formation of 4- and 6-azaindoles bearing an electron-donating group on the starting pyridylhydrazines. Two 4-azaindole natural product analogues were synthesized in a few steps and very good overall yields.

GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents

This invention relates to anti-inflammatory and analgesic compounds, especially to certain p-(sulfonyl)phenyl amino derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Novel potassium channel openers: Synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds

This report describes the synthesis and pharmacological evaluation of a series of novel potassium channel openers related to the pinacidil-type compounds. Thioureas, cyanoguanidines, and pyridine N-oxides were systematically evaluated for their effects on both the inhibition of spontaneous mechanical activity in rat portal vein (in vitro) and their antihypertensive activity (in vivo), and the structure-activity relationship for this series of compounds was discussed. Good correlation between in vitro and iv antihypertensive activity was observed for these compounds. Among them, cyanoguanidines bearing a conformationally rigid unit such as a norbornyl group generally possessed potent activity in both in vitro and in vivo studies. Especially, N-(6-amino-3-pyridyl)-N'-cyano-N''-(1-methyl-2- norbornyl)guanidine (23d) was identified as a more potent potassium channel opener in vitro (EC100 = 3 x 10-8 M) than pinacidil (EC100 = 10-7 M).